Stock INVO INVO BIOSCIENCE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News INVO Bioscience, Inc.

Equities

INVO

US44984F4019

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
0.767 USD -5.89% Intraday chart for INVO Bioscience, Inc. -10.60% -43.19%
Apr. 08 INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC CI
Apr. 05 INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC
CI
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC
CI
INVO Bioscience : Private Placement - Form 8-K
PU
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.
CI
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.
CI
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024.
CI
INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors
AQ
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc.
CI
INVO Bioscience : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
NAYA Biosciences Announces Publication Of New Data For Its CD38-Targeted Flex-NK Bispecific Antibody in The American Society of Hematology s Blood Journal
AQ
NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal
CI
INVO Bioscience, Inc. - NAYA Biosciences and ONK Therapeutics Announce Research Partnership to Advance Combination Therapy of FLEX-NK Bispecific Antibodies and Optimally Engineered Off-The-Shelf Natural Killer Cell Therapies
AQ
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
AQ
INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
PR
Top Premarket Gainers
MT
Earnings Flash (INVO) INVO BIOSCIENCE Reports Q3 Revenue $974,894
MT
INVO Reports Record Third Quarter 2023 Financial Results
PR
INVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
BestGrowthStocks.Com Issues Comprehensive Analysis Regarding INVO Biosciences Merger
AQ
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. INVO Stock
  4. News INVO Bioscience, Inc.